Short-term ingestion of Ginkgo biloba extract does not alter whole body insulin sensitivity in non-diabetic, pre-diabetic or type 2 diabetic subjects—A randomized double-blind placebo-controlled crossover study

Ingestion of Ginkgo biloba Extract (EGb 761) may increase pancreatic β-cell function in both healthy subjects with normal glucose tolerance (NGT) as well as patients with Type 2 Diabetes mellitus (T2DM). Since hyperinsulinemia is a hallmark of T2DM, it is important to verify that increased insulin production is not due to increased insulin resistance. NGT subjects ( n = 10 ; age, 44.2±13.9 years old), impaired glucose tolerance (IGT) ( n = 8 ; age 51.3±6.6 years old) and T2DM subjects ( n = 8 , 51.6±15.2 years old) completed a randomized, double-blind, placebo-controlled crossover study. After ingesting either EGb 761 (120 mg/day as a single dose) or placebo during each 3-month arm, a 2-step euglycemic insulin clamp was performed. At the low insulin infusion rate (10 mU/m 2/min) the glucose metabolic rates ( M values) were 3.5±1.5 vs. 3.0±0.5 mg/kg ( P = 0.16 ), 3.0±0.4 vs. 2.8±0.8 mg/kg ( P = 0.19 ) and 2.6±0.7 vs. 2.4±0.5 mg/kg ( P = 0.09 ) for the placebo and EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. At the high insulin infusion rate (40 mU/m 2/min) the M values were 7.3±2.3 vs. 8.1±2.5 mg/kg ( P = 0.07 ), 6.2±1.6 vs. 6.5±2.1 mg/kg ( P = 0.32 ) and 3.6±1.6 vs. 3.5±1.0 mg/kg ( P = 0.34 ) for placebo vs. EGb 761 cycles, in the NGT, IGT and T2DM subjects, respectively. The ingestion of 120 mg of EGb 761 as a single for 3 months did not produce insulin resistance in the non-diabetic or pre-diabetic subjects or exacerbate the disease in the T2DM subjects.